Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies

被引：0
|
作者：
Shigehisa Kitano
Toshio Shimizu
Takafumi Koyama
Takahiro Ebata
Satoru Iwasa
Shunsuke Kondo
Akihiko Shimomura
Yutaka Fujiwara
Noboru Yamamoto
Anne Paccaly
Siyu Li
Petra Rietschel
Tasha Sims
机构：
[1] National Cancer Center Hospital,Department of Experimental Therapeutics Koto
[2] Regeneron Pharmaceuticals,ku
[3] Inc.,undefined
[4] Regeneron Pharmaceuticals,undefined
[5] Inc.,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2021年 / 87卷
关键词：
Cemiplimab; Anti–PD-1; Immunotherapy; Advanced tumors; Japanese patients;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：53 / 64
页数：11
相关论文
共 50 条
  • [21] A first-in-human study of a novel monoclonal antibody INCSHR01210 directed against programmed cell death protein 1 (PD-1) in patients with advanced or metastatic cancer
    Lickliter, J.
    Gan, H.
    Gao, B.
    Grimison, P.
    Zou, J.
    Kallender, H.
    Sun, K.
    Chen, X.
    Behren, A.
    Fernandez-Penas, P.
    Nagrial, A.
    Voskoboynik, M.
    Woods, K.
    Millward, M.
    Meniawy, T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [22] Cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced or metastatic hepatocellular carcinoma (HCC): Data from an expansion cohort in a phase I study
    Pishvaian, M. J.
    Weiss, G. J.
    Falchook, G. S.
    Yee, N.
    Gil-Martin, M.
    Shahda, S.
    Moreno, V.
    Brana, I.
    Crittenden, M.
    Formenti, S.
    Al-Rajabi, R.
    Papadopoulos, K. P.
    Stankevich, E.
    Feng, M.
    Li, J.
    Mathias, M.
    Kroog, G.
    Lowy, I.
    Fury, M. G.
    ANNALS OF ONCOLOGY, 2018, 29
  • [23] Phase I, open-label study of MEDI0680, an anti-programmed cell death-1 (PD-1) antibody, in combination with MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in patients with advanced malignancies.
    Hamid, Omid
    Chow, Laura Quan Man
    Tavakkoli, Fatemeh
    Marshall, Shannon
    Gribbin, Matthew Joseph
    Karakunnel, Joyson Joseph
    Gray, Jhanelle Elaine
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [24] First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers
    Felip, Enriqueta
    Moreno, Victor
    Morgensztern, Daniel
    Curigliano, Giuseppe
    Rutkowski, Piotr
    Trigo, Jose Manuel
    Calvo, Aitana
    Kowalski, Dariusz
    Cortinovis, Diego
    Plummer, Ruth
    Maio, Michele
    Ascierto, Paolo A.
    Vladimirov, Vladimir, I
    Cervantes, Andres
    Zudaire, Enrique
    Hazra, Anasuya
    T'jollyn, Huybrecht
    Bandyopadhyay, Nibedita
    Greger, James G.
    Attiyeh, Edward
    Xie, Hong
    Calvo, Emiliano
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (04) : 499 - 514
  • [25] First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers
    Enriqueta Felip
    Victor Moreno
    Daniel Morgensztern
    Giuseppe Curigliano
    Piotr Rutkowski
    José Manuel Trigo
    Aitana Calvo
    Dariusz Kowalski
    Diego Cortinovis
    Ruth Plummer
    Michele Maio
    Paolo A. Ascierto
    Vladimir I. Vladimirov
    Andres Cervantes
    Enrique Zudaire
    Anasuya Hazra
    Huybrecht T’jollyn
    Nibedita Bandyopadhyay
    James G. Greger
    Edward Attiyeh
    Hong Xie
    Emiliano Calvo
    Cancer Chemotherapy and Pharmacology, 2022, 89 : 499 - 514
  • [26] A first-in-human phase 1a trial of sintilimab (IBI308), a monoclonal antibody targeting programmed death-1 (PD-1), in Chinese patients with advanced solid tumors.
    Xu, Jian-Ming
    Jia, Ru
    Wang, Yan
    Liu, Rongrui
    Zhao, Chuanhua
    Zhou, Hui
    Xu, Linxinyu
    Kong, Xuan
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [27] Cemiplimab, a Human PD-1 Monoclonal Antibody, Versus Chemotherapy in First-Line Treatment of Advanced NSCLC with PD-L1 ≥50%
    Sezer, A.
    Gogishvili, M.
    Bentsion, D.
    Kilickap, S.
    Lowczak, A.
    Gumus, M.
    Gladkov, O.
    Clingan, P.
    Sriuranpong, V.
    Rizvi, N.
    Lee, S.
    Li, S.
    Snodgrass, P.
    Navarro, M.
    Lowy, I.
    Rietschel, P.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S638 - S638
  • [28] Understanding Real-World Patients' Experience on Pembrolizumab, Anti-Programmed Death 1 Monoclonal Antibody (Anti-PD-1), for Advanced Melanoma: A Qualitative Study
    Wong, Annie
    Billett, Alexandra
    McArthur, Grant
    Milne, Donna
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 148 - 148
  • [29] Interim results of a phase 1/2 study of JNJ-63723283, an anti-PD-1 monoclonal antibody, in patients with advanced cancers.
    Calvo, Emiliano
    Moreno, Victor
    Felip, Enriqueta
    Curigliano, Giuseppe
    Morgensztern, Daniel
    Greger, James
    Bae, Kyounghwa
    Mayer, Christina Lourdes
    Marino, Jennifer
    Attiyeh, Edward F.
    Xie, Hong
    Lee, James J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
  • [30] Preliminary safety, pharmacokinetics (PK) and efficacy results from a phase I study of CS1001, an anti-programmed death ligand-1 (PD-L1) monoclonal antibody (mAb) in patients (pts) with advanced tumors
    Shen, L.
    Cao, J.
    Gong, J.
    Ji, D.
    Qin, Z.
    Dai, H.
    Wu, K.
    Xu, J.
    Yang, J.
    ANNALS OF ONCOLOGY, 2018, 29
12345